Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib plus continuous low-dose oral cyclophosphamide and dexamethasone in refractory or relapsed bortezomib-naive multiple myeloma
2008-004822-17Phase 2Active
- Sponsor
- University Medical Center of Southern Nevada
- Start
- Aug 2008
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in multiple myeloma (MM), sponsored by University Medical Center of Southern Nevada. Primary endpoint: Response during re-induction and maintenance therapy. Started Aug 2008; status: active.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2008-004822-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004822-17.